Dengue Fever Pipeline Assets Segmented by Stage, Product Type, Route of Administration and Molecule Type

 Breaking News
  • No posts were found

Dengue Fever Pipeline Assets Segmented by Stage, Product Type, Route of Administration and Molecule Type

March 22
05:05 2023
Dengue Fever Pipeline Assets Segmented by Stage, Product Type, Route of Administration and Molecule Type

DelveInsight’s, “Dengue Fever Pipeline Insight 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Dengue Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Dengue Fever Emerging drugs, the Dengue Fever pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Dengue Fever pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Dengue Fever Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Dengue Fever clinical trials studies, Dengue Fever NDA approvals (if any), and product development activities comprising the technology, Dengue Fever collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Dengue Fever Pipeline Report

 

  • DelveInsight’s Dengue Fever Pipeline analysis depicts a robust space with 10+ active players proactively working to develop 10+ pipeline treatment therapies.

 

  • The leading Dengue Fever Companies include Kino Pharma, Emergex Vaccines, Abivax, Plex Pharmaceuticals, Takeda, Merck Sharp & Dohme, Immunoforge, Chugai Pharmaceutical Co., Ltd, Codagenix, Biotron Ltd, GlaxoSmithKline, Ennaid therapeutics, AbViro LLC, Medigen Vaccine Biologics Corp., Atea Pharmaceuticals, Visterra, Janssen Research & Development, Globavir Biosciences, Serum Institute of India, BioNet Asia, and others.

 

  • Promising Dengue Fever pipeline therapies include Research programs: anti-RNA virus therapeutics, viral budding inhibitors, ABX220, Infectious diseases therapeutics program, CDX DENV,  AT-752, VIS513, JNJ-64281802, TV003, V 503, TAK-003, AV-1, PepGNP-Dengue, GBV 006, Dengushield, Pentavalent dengue-zika vaccine, and others

 

  • The Dengue Fever companies and academics are working to assess challenges and seek opportunities that could influence Dengue Fever R&D. The Dengue Fever pipeline therapies under development are focused on novel approaches to treat/improve Dengue Fever.

 

Request a sample and discover the recent breakthroughs happening in the Dengue Fever Pipeline landscape @ Dengue Fever Pipeline Outlook Report

 

Dengue Fever Overview

Dengue Virus (DENV) is an arbovirus (arthropod-borne virus). Four serotypes of DENV are responsible for the infectious disease called dengue that annually affects nearly 400 million people worldwide. Dengue fever is a common mosquito-borne illness in many tropical and subtropical countries. Classic dengue fever, or “break bone fever,” is characterized by acute onset of high fever 3–14 days after the bite of an infected mosquito.

 

Recent Developmental Activities in the Dengue Fever Treatment Landscape

 

  • In June 2021, Emergex Vaccines Holding Limited announced that it has achieved regulatory approval for a Phase I clinical trial of its Dengue vaccine. The study has received approval from Swiss regulatory agencies and the first participants are expected to be enrolled soon.

 

  • In May 2021, Takeda Pharmaceutical Company Limited announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual’s previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase 3 clinical trial namely – Tetravalent Immunization against Dengue Efficacy Study (TIDES). TIDES enrolled more than 20,000 healthy children and adolescents ages four to 16 years in dengue-endemic countries in Latin America and Asia.

 

  • In August 2021, Atea Pharmaceuticals, Inc. announced the publication of data demonstrating the in vitro and in vivo activity of AT-752 against dengue virus infection, in the journal, Antimicrobial Agents and Chemotherapy. The article titled, “Evaluation of AT-752, a double prodrug of a guanosine nucleotide analog with in vitro and in vivo activity against dengue and other flaviviruses,” can be accessed here. The published data demonstrate that AT-752 has potent in vitro activity against multiple dengue virus serotypes and other flaviviruses tested, reduces viremia, and improves survival in an animal model of dengue disease.

 

  • In October 2021, Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced today, in collaboration with the KU Leuven Rega Institute and the KU Leuven Centre for Drug Design and Discovery (CD3), the publication of new preclinical data in the journal Nature showing that an early-stage compound with a novel mechanism of action could potentially treat all serotypes of dengue fever and provide a period of protection against acquiring the dengue virus. Janssen is now moving its dengue program into clinical development.

 

For further information, refer to the detailed Dengue Fever Drugs Launch, Dengue Fever Developmental Activities, and Dengue Fever News, click here for Dengue Fever Ongoing Clinical Trial Analysis

 

Dengue Fever Emerging Drugs Profile

 

  • TAK003: Takeda

Takeda’s TAK-003 is an investigational live-attenuated tetravalent dengue vaccine, preventing dengue fever caused by any of the four serotypes of the dengue virus of which can cause dengue fever or Severe Dengue. Takeda’s current clinical development program consists of five Phase 3 trials of TAK003 Clinical Phase 1 and 2 data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes.

 

  • V180: Merck Sharp & Dohme

Merck & Co’s adjuvanted, tetravalent subunit vaccine V180 comprises truncated forms of envelope proteins (DEN-80E), derived from strains of all four dengue virus serotypes. The DEN-80E subunits are expressed from plasmids in the Drosophila S2 cell expression system and are formulated with either ISCOMATRIX and Alhydrogel.V180’s more compact dosing schedule could make it a more attractive alternative to Dengvaxia, particularly for travelers. However, its current three-dose schedule could still be improved to reduce the risk of non-compliance. It is believed that V180 would achieve its greatest commercial potential as part of a heterologous prime-boost strategy with TetraVax-DV. V180 is currently in Phase I development .

 

  • AV1: AbViro LLC

AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact. Currently Av1 is being studied in phase I in adult healthy individuals.

 

Dengue Fever Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Dengue Fever. The companies which have their Dengue Fever drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Takeda and others.

 

Find out more about the Dengue Fever Pipeline Segmentation, Therapeutics Assessment, and Dengue Fever Emerging Drugs @ Dengue Fever Treatment Landscape

 

Scope of the Dengue Fever Pipeline Report

 

  • Coverage- Global

 

  • Dengue Fever Companies- Kino Pharma, Emergex Vaccines, Abivax, Plex Pharmaceuticals, Takeda, Merck Sharp & Dohme, Immunoforge, Chugai Pharmaceutical Co., Ltd, Codagenix, Biotron Ltd, GlaxoSmithKline, Ennaid therapeutics, AbViro LLC, Medigen Vaccine Biologics Corp., Atea Pharmaceuticals, Visterra, Janssen Research & Development, Globavir Biosciences, Serum Institute of India, BioNet Asia, and others.

 

  • Dengue Fever pipeline therapies- Research programs: anti-RNA virus therapeutics, viral budding inhibitors, ABX220, Infectious diseases therapeutics program, CDX DENV,  AT-752, VIS513, JNJ-64281802, TV003, V 503, TAK-003, AV-1, PepGNP-Dengue, GBV 006, Dengushield, Pentavalent dengue-zika vaccine, and others.

 

  • Dengue Fever Pipeline Segmentation- Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

Dive deep into rich insights for drugs for Dengue Fever Pipeline Companies and Therapies, click here @ Dengue Fever Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Dengue Fever: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Dengue Fever – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Dengue Fever Collaboration Deals
  9. Late Stage Products (Phase III)
  10. TAK003: Takeda
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. V180: Merck Sharp & Dohme
  14. Drug profiles in the detailed report…..
  15. Pre-clinical and Discovery Stage Products
  16. Drug profiles in the detailed report…..
  17. Inactive Products
  18. Dengue Fever Key Companies
  19. Dengue Fever Key Products
  20. Dengue Fever- Unmet Needs
  21. Dengue Fever- Market Drivers and Barriers
  22. Dengue Fever- Future Perspectives and Conclusion
  23. Dengue Fever Analyst Views
  24. Dengue Fever Key Companies
  25. Appendix

 

Got Queries? Find out the related information on Dengue Fever Mergers and acquisitions, Dengue Fever Licensing Activities @ Dengue Fever Emerging Drugs, and Recent Trends

 

 About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories